These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

144 related articles for article (PubMed ID: 23076292)

  • 21. Alendronate in primary hyperparathyroidism: a double-blind, randomized, placebo-controlled trial.
    Khan AA; Bilezikian JP; Kung AW; Ahmed MM; Dubois SJ; Ho AY; Schussheim D; Rubin MR; Shaikh AM; Silverberg SJ; Standish TI; Syed Z; Syed ZA
    J Clin Endocrinol Metab; 2004 Jul; 89(7):3319-25. PubMed ID: 15240609
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Effects of teriparatide, alendronate, or both on bone turnover in osteoporotic men.
    Finkelstein JS; Leder BZ; Burnett SM; Wyland JJ; Lee H; de la Paz AV; Gibson K; Neer RM
    J Clin Endocrinol Metab; 2006 Aug; 91(8):2882-7. PubMed ID: 16684825
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Persistently increased bone turnover and low bone density in long-term survivors to kidney transplantation.
    Giannini S; D'Angelo A; Carraro G; Antonello A; Di Landro D; Marchini F; Plebani M; Zaninotto M; Rigotti P; Sartori L; Crepaldi G
    Clin Nephrol; 2001 Nov; 56(5):353-63. PubMed ID: 11758005
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Additional beneficial effects of alendronate in growth hormone (GH)-deficient adults with osteoporosis receiving long-term recombinant human GH replacement therapy: a randomized controlled trial.
    Biermasz NR; Hamdy NA; Janssen YJ; Roelfsema F
    J Clin Endocrinol Metab; 2001 Jul; 86(7):3079-85. PubMed ID: 11443170
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Diagnostic Accuracy of Biomarkers and Imaging for Bone Turnover in Renal Osteodystrophy.
    Salam S; Gallagher O; Gossiel F; Paggiosi M; Khwaja A; Eastell R
    J Am Soc Nephrol; 2018 May; 29(5):1557-1565. PubMed ID: 29555831
    [No Abstract]   [Full Text] [Related]  

  • 26. Alendronate prevents further bone loss in renal transplant recipients.
    Giannini S; D'Angelo A; Carraro G; Nobile M; Rigotti P; Bonfante L; Marchini F; Zaninotto M; Dalle Carbonare L; Sartori L; Crepaldi G
    J Bone Miner Res; 2001 Nov; 16(11):2111-7. PubMed ID: 11697808
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Effect of whole-body vibration exercise on lumbar bone mineral density, bone turnover, and chronic back pain in post-menopausal osteoporotic women treated with alendronate.
    Iwamoto J; Takeda T; Sato Y; Uzawa M
    Aging Clin Exp Res; 2005 Apr; 17(2):157-63. PubMed ID: 15977465
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Alendronate with and without cholecalciferol for osteoporosis: results of a 15-week randomized controlled trial.
    Recker R; Lips P; Felsenberg D; Lippuner K; Benhamou L; Hawkins F; Delmas PD; Rosen C; Emkey R; Salzmann G; He W; Santora AC
    Curr Med Res Opin; 2006 Sep; 22(9):1745-55. PubMed ID: 16968578
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Profile of chronic kidney disease related-mineral bone disorders in newly diagnosed advanced predialysis diabetic kidney disease patients: A hospital based cross-sectional study.
    Ray S; Beatrice AM; Ghosh A; Pramanik S; Bhattacharjee R; Ghosh S; Raychaudhury A; Mukhopadhyay S; Chowdhury S
    Diabetes Metab Syndr; 2017 Dec; 11 Suppl 2():S931-S937. PubMed ID: 28728874
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Two-year retrospective study of the effect of preemptive kidney transplantation and pretransplant mineral bone factors on calcium in post-kidney transplant recipients.
    Tsujita M; Goto N; Futamura K; Okada M; Hiramitsu T; Narumi S; Uchida K; Morozumi K; Watarai Y
    Clin Exp Nephrol; 2020 Sep; 24(9):836-841. PubMed ID: 32342291
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Clinical results of alendronate monotherapy and combined therapy with menatetrenone (VitK₂) in postmenopausal RA patients.
    Suzuki K; Tsuji S; Fukushima Y; Nakase T; Hamada M; Tomita T; Yoshikawa H
    Mod Rheumatol; 2013 May; 23(3):450-5. PubMed ID: 22692649
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Cost-effectiveness of sequential treatment with abaloparatide followed by alendronate vs. alendronate monotherapy in women at increased risk of fracture: A US payer perspective.
    Hiligsmann M; Williams SA; Fitzpatrick LA; Silverman SS; Weiss R; Reginster JY
    Semin Arthritis Rheum; 2020 Jun; 50(3):394-400. PubMed ID: 32160943
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Oral calcitriol versus oral alfacalcidol for the treatment of secondary hyperparathyroidism in patients receiving hemodialysis: a randomized, crossover trial.
    Moe S; Wazny LD; Martin JE
    Can J Clin Pharmacol; 2008; 15(1):e36-43. PubMed ID: 18192704
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Bone turnover markers are associated with bone density, but not with fracture in end stage kidney disease: a cross-sectional study.
    Jørgensen HS; Winther S; Bøttcher M; Hauge EM; Rejnmark L; Svensson M; Ivarsen P
    BMC Nephrol; 2017 Sep; 18(1):284. PubMed ID: 28874132
    [TBL] [Abstract][Full Text] [Related]  

  • 35. EFFECTS OF LONG-TERM ALENDRONATE TREATMENT ON A LARGE SAMPLE OF PEDIATRIC PATIENTS WITH OSTEOGENESIS IMPERFECTA.
    Lv F; Liu Y; Xu X; Wang J; Ma D; Jiang Y; Wang O; Xia W; Xing X; Yu W; Li M
    Endocr Pract; 2016 Dec; 22(12):1369-1376. PubMed ID: 27482608
    [TBL] [Abstract][Full Text] [Related]  

  • 36. ACTIVExtend: 24 Months of Alendronate After 18 Months of Abaloparatide or Placebo for Postmenopausal Osteoporosis.
    Bone HG; Cosman F; Miller PD; Williams GC; Hattersley G; Hu MY; Fitzpatrick LA; Mitlak B; Papapoulos S; Rizzoli R; Dore RK; Bilezikian JP; Saag KG
    J Clin Endocrinol Metab; 2018 Aug; 103(8):2949-2957. PubMed ID: 29800372
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Effects of calcitriol on type 5b tartrate-resistant acid phosphatase and interleukin-6 in secondary hyperparathyroidism.
    Lu KC; Tseng CF; Wu CC; Yeung LK; Chen JS; Chao TY; Janckila AJ; Yam LT; Chu P
    Blood Purif; 2006; 24(5-6):423-30. PubMed ID: 16888370
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Bone metabolism dynamics in the early post-transplant period following kidney and liver transplantation.
    Schreiber PW; Bischoff-Ferrari HA; Boggian K; Bonani M; van Delden C; Enriquez N; Fehr T; Garzoni C; Hirsch HH; Hirzel C; Manuel O; Meylan P; Saleh L; Weisser M; Mueller NJ;
    PLoS One; 2018; 13(1):e0191167. PubMed ID: 29338022
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Rationale for Raising Current Clinical Practice Guideline Target for Serum 25-Hydroxyvitamin D in Chronic Kidney Disease.
    Strugnell SA; Sprague SM; Ashfaq A; Petkovich M; Bishop CW
    Am J Nephrol; 2019; 49(4):284-293. PubMed ID: 30878999
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Efficacy and safety of a once-yearly i.v. Infusion of zoledronic acid 5 mg versus a once-weekly 70-mg oral alendronate in the treatment of male osteoporosis: a randomized, multicenter, double-blind, active-controlled study.
    Orwoll ES; Miller PD; Adachi JD; Brown J; Adler RA; Kendler D; Bucci-Rechtweg C; Readie A; Mesenbrink P; Weinstein RS
    J Bone Miner Res; 2010 Oct; 25(10):2239-50. PubMed ID: 20499357
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.